Traditional and patient-centred outcomes with three classes of asthma medication

European Respiratory Journal

Volumn 26, Issue 1, 2005, Pages 36-44

  Jenkins, C R ^a,b   Thien, F C K ^a,c   Wheatley, J R ^a,d   Reddel, H K ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Asthma treatment; Lung function; Patient centred outcomes; Quality of life

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LONG ACTING DRUG; MONTELUKAST; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; INHALER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT CARE; PEAK EXPIRATORY FLOW; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; THRUSH;

ACETATES; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ASTHMA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEW SOUTH WALES; PATIENT SATISFACTION; PATIENT-CENTERED CARE; PROBABILITY; QUALITY OF LIFE; QUINOLINES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 21744447554     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00144704     Document Type: Article

References (31)

1. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
2. Demoly P, Crestani B, Leroyer C, Magnan A, Mounedji N, Humbert M. Control and exacerbation of asthma: a survey of more than 3000 French physicians. Allergy 2004; 59: 920-926.
3. Global Initiative for Asthma. Workshop Report. Global strategy for asthma management and prevention. 2002 Revision. National Institutes of Health, National Heart, Lung, and Blood Institute. NIH Publication No. 02-3659.
4. National Asthma Council Australia. Asthma Management Handbook. Melbourne, Australia, National Asthma Council Australia Ltd, 2002.
5. National Asthma Education and Prevention Program Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD, USA, National Institutes of Health 1997; pp. 97-4051.
6. Rubin BK. What does it mean when a patient says "My asthma medication is not working?". Chest 2004; 126: 972-981.
7. Osman LM, McKenzie L, Cairns J, et al. Patient weighting of importance of asthma symptoms. Thorax 2001; 56: 138-142.
8. Strunk RC, Korenblat PE. Choice of a medication to treat asthma: is an improvement in symptoms sufficient for deciding? J Allergy Clin Immunol 2002; 110: 832-833.
9. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004; 23: 287-291.
10. Clark NM, Gong M. Management of chronic disease by practitioners and patients: are we teaching the wrong things? BMJ 2000; 320: 572-575.
11. Steven K, Morrison J, Drummond N. Lay versus professional motivation for asthma treatment: a cross-sectional, qualitative study in a single Glasgow general practice. Family Practice 2002; 19: 172-177.
12. Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol 1992; 45: 461-472.
13. Yan K, Salome CM, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax 1983; 38: 760-765.
14. Jones B, Kenward MG. Design and Analysis of Crossover Trials. London, UK, Chapman and Hall, 1989.
15. Gillings DB, Koch GG. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information Journal 1991; 25: 411-424.
16. Patel HI. Use of baseline measurements in two-period crossover design in clinical trials. Commun Statis Theor Meth 1983; 112: 2693-2712.
17. Quanjer PH, Dalhuijsen A, Van Zomeren B. Summary equations of reference values. Bull Europ Physiopathol Respir 1983; 19: Suppl. 5, 45-51.
18. Food and Drug Administration. MedWatch: The FDA safety information and adverse event reporting program. 2003 Safety Alert - Serevent (salmeterol xinafoate). www.fda.gov/medwatch/SAFETY/2003/serevent.htm. Date last updated: January 23 2003; Date last accessed: October 10 2004.
19. Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226-235 (published erratum appears in Eur Respir J 2000; 16: 579).
20. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2002; 3: CD002314.
21. Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Resp Crit Care Med 1999; 159: 79-86.
22. Pearlman DS, Stricker W, Weinstein S, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999; 82: 257-265.
23. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The dutch paediatric asthma study group. Am J Resp Crit Care Med 1997; 156: 688-695.
24. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583-2593.
25. Bailey WC, Higgins DM, Richards BM, Richards JM, Jr. Asthma severity: a factor analytic investigation. Am J Med 1992; 93: 263-269.
26. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999; 103: 232-237.
27. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999; 159: 22-30.
28. Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long term treatment with inhaled corticosteroids. Thorax 1999; 54: 103-107.
29. Dorinsky PM, Edwards LD, Yancey SW, Rickard KA. Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy. Clin Ther 2001; 23: 701-714.
30. Vollmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Resp Crit Care Med 1999; 160: 1647-1652.
31. Bateman ED, Frith LF, Braunstein GL. Achieving guideline-based asthma control: does the patient benefit? Eur Respir J 2002; 20: 588-595.